R50.84 Febrile nonhemolytic transfusion reaction

Name of the Condition

• Febrile Nonhemolytic Transfusion Reaction

Summary

Febrile nonhemolytic transfusion reaction (FNHTR) is a febrile response occurring during or after a blood transfusion, where hemolysis is not present. It is the most common type of transfusion reaction and is typically attributed to the recipient's immune response to white blood cells or other components in the transfused blood product. The fever is usually self-limiting and resolves without severe sequelae.

Causes

FNHTR is primarily caused by the recipient's immune system reacting to leukocytes (white blood cells) or cytokines present in the transfused blood. These reactions may be due to preformed antibodies in the recipient that target donor leukocytes, leading to the release of pyrogens (fever-inducing substances). Other contributing factors include the accumulation of cytokines in stored blood products, which can trigger an inflammatory response upon transfusion.

Risk Factors

• Prior exposure to blood products or pregnancy (increased likelihood of antibody formation).
• Receiving multiple transfusions over time.
• Transfusion of blood products with high leukocyte content.
• Underlying conditions that may predispose to immune reactions (e.g., certain infections or inflammatory diseases).
• Use of blood products from donors with high cytokine levels.

Symptoms

• Sudden onset of fever during or within hours of transfusion.
• Chills, rigors, or shivering.
• Malaise or general discomfort.
• Headache or body aches.
• In some cases, mild respiratory or cardiovascular symptoms (e.g., tachycardia).

Diagnosis

Diagnosis is based on clinical presentation and exclusion of other causes. Key steps include stopping the transfusion, assessing vital signs, and ruling out hemolytic reactions (e.g., via direct antiglobulin test or hemoglobinuria). Blood cultures may be obtained to exclude infectious causes, and the reaction is confirmed if fever resolves without other complications. Documentation should specify the timing relative to transfusion and absence of hemolysis.

Treatment Options

• Discontinuation of the transfusion immediately.
• Administration of antipyretics (e.g., acetaminophen) to manage fever.
• Monitoring vital signs and symptoms until resolution.
• For severe reactions, additional supportive care (e.g., oxygen, fluids) may be provided.
• Future transfusions may use leukoreduced or washed blood products to prevent recurrence.

Prognosis and Follow-Up

FNHTR generally has a good prognosis, with symptoms resolving within hours to days. Most patients recover fully without long-term effects. Follow-up involves monitoring for recurrence and ensuring the reaction is documented in the medical record. If symptoms persist or worsen, further evaluation for alternative causes (e.g., infection) is necessary.

Complications

• Rarely, severe reactions may lead to hypotension or respiratory distress.
• In immunocompromised patients, fever may mask or complicate underlying infections.
• Repeated reactions may necessitate changes in transfusion protocols (e.g., use of specialized blood products).

Lifestyle & Prevention

• For patients with a history of FNHTR, future transfusions should use leukoreduced or irradiated blood products to minimize immune reactions.
• Pre-medication with antipyretics or antihistamines may be considered in high-risk cases.
• Prompt recognition and management of reactions can reduce discomfort and prevent complications.

When to Seek Professional Help

Seek immediate medical attention if fever is accompanied by severe symptoms (e.g., difficulty breathing, chest pain, or hypotension) during or after a transfusion. Persistent fever beyond 24 hours or signs of infection (e.g., worsening malaise, new rash) also warrant evaluation.

Tips for Medical Coders

Document the timing of the reaction (during or after transfusion), absence of hemolysis, and any interventions (e.g., antipyretics). Ensure the code R50.84 is used only when the reaction is confirmed as febrile nonhemolytic and not attributed to other causes (e.g., infection or allergic reaction). Include details about blood product type and any modifications (e.g., leukoreduction) in the medical record for clarity.